BlackRock’s CinCor Pharma, Inc. Common Stock CINC Stock Holding History

BlackRock’s Portfolio CINC Stock Details CINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,783,419	Closed	-$21.9M	–	5798
2022 Q4	$21.9M	Buy	1,783,419 +464,413	+35%	+$11.1M	﹤0.01%	2985
2022 Q3	$43.3M	Buy	1,319,006 +476,741	+57%	+$13.5M	﹤0.01%	2548
2022 Q2	$15.9M	Buy	842,265 +166,255	+25%	+$3.18M	﹤0.01%	3214
2022 Q1	$11.9M	Buy	+676,010	New	+$13.9M	﹤0.01%	3484

BlackRock's CINC Position: Q1 2023 in Review

BlackRock sold out of CinCor Pharma, Inc. Common Stock (CINC) in Q1 2023, closing a stake of 1,783,419 shares — an estimated $21.9M sold.

BlackRock first reported a position in CINC in Q1 2022 and held it in 4 quarters. The position peaked at $43.3M in Q3 2022. 0 funds tracked by Wall St. Rank hold CINC as of Q1 2023.

BlackRock reported no remaining CinCor Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
BlackRock sold 1,783,419 CinCor Pharma, Inc. Common Stock shares in Q1 2023, an estimated $21.9M.
BlackRock first reported a position in CinCor Pharma, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
BlackRock's CinCor Pharma, Inc. Common Stock position peaked at $43.3M in Q3 2022.
0 funds tracked by Wall St. Rank held CinCor Pharma, Inc. Common Stock as of Q1 2023.

Based on BlackRock's 13F filing for Q1 2023, filed 12 May 2023.